Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 New TERN-701 data from ongoing U.S. healthy volunteer PK study shows improved drug-drug interaction profile compared to asciminib Introduces TERN-601 Phase 2 FALCON obesity study design; on track to initiate study in early 2Q25 with 12-week data expected 2H25 Cash and cash equivalents expected to provide runway into 2028 FOSTER CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- ...